Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma

World Journal of Hepatology

Volumn 8, Issue 27, 2016, Pages 1119-1127

  Gao, Chun ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Diabetes mellitus; Hepatocellular carcinoma; Molecular mechanism; Molecular pathological epidemiology; Risk factor

Indexed keywords

EID: 84992395293     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v8.i27.1119     Document Type: Review

References (100)

1. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-265 [PMID: 20351699 DOI: 10.1038/nrclinonc.2010.41]
2. Menendez KR, García M, Spatz S, Tablante NL. Molecular epidemiology of infectious laryngotracheitis: a review. Avian Pathol 2014; 43: 108-117 [PMID: 24460399 DOI: 10.1080/03079457.201 4.886004]
3. Izzotti A, Neri M, Vecchio D, Puntoni R. Molecular epidemiology in cancer research (review). Int J Oncol 1997; 11: 1053-1069 [PMID: 21528304]
4. Lloyd C, Cullinan P. Year in review 2014: basic science and epidemiology. Thorax 2015; 70: 581-584 [PMID: 25977391 DOI: 10.1136/thoraxjnl-2015-207222]
5. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010; 102: 365-367 [PMID: 20208016 DOI: 10.1093/jnci/djq031]
6. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60: 397-411 [PMID: 21036793 DOI: 10.1136/gut.2010.217182]
7. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008; 26: 5713-5720 [PMID: 18955444 DOI: 10.1200/JCO.2008.18.2675]
8. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011; 305: 1685-1694 [PMID: 21521850 DOI: 10.1001/jama.2011.513]
9. Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, McLaughlin JR, Haile RW, Jacobs EJ, Newcomb PA, Potter JD, Le Marchand L, Green RC, Parfrey P, Younghusband HB, Cotterchio M, Gallinger S, Jenkins MA, Hopper JL, Baron JA, Thibodeau SN, Lindor NM, Limburg PJ, Martinez ME, Colon Cancer Family R. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 2010; 102: 391-400 [PMID: 20208017 DOI: 10.1093/jnci/djq011]
10. Gao C. Molecular pathological epidemiology: an interdisciplinary field for study of hepatocellular carcinoma. Austin J Gastroenterol 2015; 2: 1040
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
12. Zhang H, Gao C, Fang L, Yao SK. Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus. World J Gastroenterol 2013; 19: 2395-2403 [PMID: 23613635 DOI: 10.3748/wjg.v19.i15.2395]
13. Madkhali AA, Fadel ZT, Aljiffry MM, Hassanain MM. Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol 2015; 21: 11-17 [PMID: 25672233 DOI: 10.4103/1319-3767.151216]
14. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-823 [PMID: 14623619]
15. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-353 [PMID: 19220670 DOI: 10.1111/j.1440-1746.2009.05784.x]
16. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539 [PMID: 15753540 DOI: 10.1136/gut.2004.052167]
17. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851 [PMID: 18328931 DOI: 10.1016/S0140-6736(08)60383-9]
18. Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y, Uchiyama K. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol 2016; 25: 24-29 [PMID: 26979637 DOI: 10.1016/j.suronc.2015. 12.002]
19. Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Liu CJ, Kao JH. Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. Medicine (Baltimore) 2016; 95: e2995 [PMID: 26962809 DOI: 10.1097/MD.0000000000002995]
20. Gao C, Fang L, Zhao HC, Li JT, Yao SK. Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int 2013; 12: 385-393 [PMID: 23924496]
21. Gao C, Yao SK. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int 2009; 8: 465-473 [PMID: 19822488]
22. Gao C, Zhao HC, Li JT, Yao SK. Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis. World J Gastroenterol 2010; 16: 4467-4475 [PMID: 20845516]
23. Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87 [PMID: 23137049 DOI: 10.3109/00365521.2012.719926]
24. Lawson DH, Gray JM, McKillop C, Clarke J, Lee FD, Patrick RS. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986; 61: 945-955 [PMID: 2819932]
25. Fujino Y, Mizoue T, Tokui N, Yoshimura T. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 2001; 17: 374-379 [PMID: 11747142]
26. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-2467 [PMID: 11513191 DOI: 10.1111/j.1572-0241.2001.04054.x]
27. Yu L, Sloane DA, Guo C, Howell CD. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol 2006; 4: 355-360 [PMID: 16527700 DOI: 10.1016/j.cgh.2005.12.022]
28. Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970; 44: 673-686 [PMID: 11515436]
29. Ragozzino M, Melton LJ, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982; 35: 13-19 [PMID: 7068798]
30. Lu SN, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang WY, Hsu ST. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62: 2051-2055 [PMID: 2844388]
31. Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni JF. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-1477 [PMID: 8841022]
32. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468 [PMID: 14762783]
33. Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B, Cheung R, Wong RJ. Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. Dig Dis Sci 2016; 61: 636-645 [PMID: 26703125 DOI: 10.1007/s10620-015-3983-3]
34. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964-973 [PMID: 22991257 DOI: 10.1002/hep.26087]
35. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009; 18: 2054-2060 [PMID: 19549812 DOI: 10.1158/1055-9965.EPI-08-1131]
36. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121 [PMID: 18505690 DOI: 10.1053/j.gastro.2008.03.073]
37. Kawamura Y, Arase Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 2010; 123: 951-956.e1 [PMID: 20920698 DOI: 10.1016/j.amjmed.2010.05.013]
38. Ko WH, Chiu SY, Yang KC, Chen HH. Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case-control study in hepatitis endemic area. Hepatol Res 2012; 42: 774-781 [PMID: 22469194 DOI: 10.1111/j.1872-034X.2012.00979.x]
39. Konishi I, Hiasa Y, Shigematsu S, Hirooka M, Furukawa S, Abe M, Matsuura B, Michitaka K, Horiike N, Onji M. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int 2009; 29: 1194-1201 [PMID: 19422477 DOI: 10.1111/j.1478-3231.2009.02043.x]
40. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, Abiru S, Nakagawa Y, Shigeno M, Miyazoe S, Ichikawa T, Ishikawa H, Nakao K, Eguchi K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-3043 [PMID: 12784339 DOI: 10.1002/cncr.11427]
41. van den Tweel JG, Taylor CR. A brief history of pathology: Preface to a forthcoming series that highlights milestones in the evolution of pathology as a discipline. Virchows Arch 2010; 457: 3-10 [PMID: 20499087 DOI: 10.1007/s00428-010-0934-4]
42. Jiang C, Gu J. History and current state of pathology in China. Virchows Arch 2013; 463: 599-608 [PMID: 23881278 DOI: 10.1007/s00428-013-1449-6]
43. Campbell IL, Harrison LC. Molecular pathology of type 1 diabetes. Mol Biol Med 1990; 7: 299-309 [PMID: 2233244]
44. Adorini L, Gregori S, Harrison LC. Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 2002; 8: 31-38 [PMID: 11796264]
45. Wiltshire S, Bell JT, Groves CJ, Dina C, Hattersley AT, Frayling TM, Walker M, Hitman GA, Vaxillaire M, Farrall M, Froguel P, McCarthy MI. Epistasis between type 2 diabetes susceptibility Loci on chromosomes 1q21-25 and 10q23-26 in northern Europeans. Ann Hum Genet 2006; 70: 726-737 [PMID: 17044847 DOI: 10.1111/j.1469-1809.2006.00289.x]
46. Lima SM, Grisi DC, Kogawa EM, Franco OL, Peixoto VC, Gonçalves-Júnior JF, Arruda MP, Rezende TM. Diabetes mellitus and inflammatory pulpal and periapical disease: a review. Int Endod J 2013; 46: 700-709 [PMID: 23442003 DOI: 10.1111/iej.12072]
47. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009; 10: 353-358 [PMID: 19434079 DOI: 10.1038/nrg2574]
48. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010; 10: 353-361 [PMID: 20414203 DOI: 10.1038/nrc2840]
49. Sandhu MS. Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 2005; 9: 44-54 [PMID: 15879687 DOI: 10.1159/000085755]
50. Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36 Suppl 2: S233-S239 [PMID: 23882051 DOI: 10.2337/dcS13-2001]
51. Field AE, Camargo CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA 2013; 310: 2147-2148 [PMID: rfseq 24189835 DOI: 10.1001/jama.2013.281501]
52. Wu ZY, Wang MH, Qi HM, Wu MH, Ge YZ, Li HT. Relationship between hOGG1 Ser326Cys gene polymorphism and coronary artery lesions in patients with diabetes mellitus. Int J Clin Exp Med 2015; 8: 18629-18637 [PMID: 26770476]
53. Remo A, Pancione M, Zanella C, Vendraminelli R. Molecular pathology of colorectal carcinoma. A systematic review centred on the new role of the pathologist. Pathologica 2012; 104: 432-441 [PMID: 23547429]
54. Paral J, Slaninka I, Kalabova H, Hadzi-Nikolov D. Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options. Acta Gastroenterol Belg 2010; 73: 349-359 [PMID: 21086937]
55. Ray A, Manjila S, Hdeib AM, Radhakrishnan A, Nock CJ, Cohen ML, Sloan AE. Extracranial metastasis of gliobastoma: Three illustrative cases and current review of the molecular pathology and management strategies. Mol Clin Oncol 2015; 3: 479-486 [PMID: 26137254 DOI: 10.3892/mco.2015.494]
56. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27 [PMID: 18165277 DOI: 10.2353/jmoldx.2008.070082]
57. Baudhuin LM, Donato LJ, Uphoff TS. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev Mol Diagn 2012; 12: 25-37 [PMID: 22133117 DOI: 10.1586/ERM.11.85]
58. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 2010; 10: 33-48 [PMID: 20014921 DOI: 10.1586/erm.09.69]
59. Metodiev MV. Biomarkers research in Europe: focus on personalized medicine. Expert Rev Mol Diagn 2011; 11: 689-690 [PMID: 21902529 DOI: 10.1586/erm.11.55]
60. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008; 21 Suppl 2: S23-S30 [PMID: 18437170 DOI: 10.1038/modpathol.2008.14]
61. Gulley ML, Braziel RM, Halling KC, Hsi ED, Kant JA, Nikiforova MN, Nowak JA, Ogino S, Oliveira A, Polesky HF, Silverman L, Tubbs RR, Van Deerlin VM, Vance GH, Versalovic J. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med 2007; 131: 852-863 [PMID: 17550311 DOI: 10.1043/154 3-2165(2007)131]
62. Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am J Clin Pathol 2011; 135: 668-672 [PMID: 21502420 DOI: 10.1309/AJCP9GDNLWB4GACI]
63. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157-1166 [PMID: 19336554 DOI: 10.1158/1055-9965. EPI-08-1005]
64. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20: 1071-1082 [PMID: 19343511 DOI: 10.1007/s10552-009-9331-1]
65. Pervaiz F, Rehmani S, Majid S, Anwar H. Evaluation of Hormone Receptor Status (ER/PR/HER2-neu) in Breast Cancer in Pakistan. J Pak Med Assoc 2015; 65: 747-752 [PMID: 26160085]
66. Ichihara E, Lovly CM. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Cancer Discov 2015; 5: 694-696 [PMID: 26152920 DOI: 10.1158/2159-8290.CD-15-0616]
67. Li W, Qu J, Xu Z. Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. J Thorac Dis 2015; 7: 875-880 [PMID: 26101643 DOI: 10.3978/j.issn.2072-1439.2015.04.49]
68. Webber EM, Kauffman TL, O'Connor E, Goddard KA. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 2015; 15: 156 [PMID: 25884995 DOI: 10.1186/s12885-015-1093-4]
69. Yamane LS, Scapulatempo-Neto C, Alvarenga L, Oliveira CZ, Berardinelli GN, Almodova E, Cunha TR, Fava G, Colaiacovo W, Melani A, Fregnani JH, Reis RM, Guimarães DP. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. Oncol Rep 2014; 32: 1419-1426 [PMID: 25050586 DOI: 10.3892/or.2014.3338]
70. Genther Williams SM, Kuznicki AM, Andrade P, Dolinski BM, Elbi C, O'Hagan RC, Toniatti C. Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status. Cancer Cell Int 2015; 15: 14 [PMID: 25685067 DOI: 10.1186/s12935-015-0162-8]
71. Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A. Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes Cancer 2014; 5: 273-284 [PMID: 25221645]
72. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159 [PMID: 18337604 DOI: 10.1056/NEJMra072067]
73. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554 [PMID: 15016963 DOI: 10.1126/science.1096502]
74. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113 [PMID: 17932254 DOI: 10.1126/science.1145720]
75. Ojanguren I, Castellà E, Llatjós M, Ariza A, Navas Palacios JJ. p53 immunoreaction in hepatocellular carcinoma and its relationship to etiologic factors. A fine needle aspiration study. Acta Cytol 1996; 40: 1148-1153 [PMID: 8960021]
76. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
77. Jiang N, Sun R, Sun Q. Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Des Devel Ther 2014; 8: 2295-2302 [PMID: 25484575 DOI: 10.2147/DDDT.S69004]
78. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]
79. Yu XJ, Fang F, Tang CL, Yao L, Yu L, Yu L. dbHCCvar: a comprehensive database of human genetic variations in hepatocellular carcinoma. Hum Mutat 2011; 32: E2308-E2316 [PMID: 21936021 DOI: 10.1002/humu.21595]
80. Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, Wen T, Xu M, Wang W, Yang J. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and metaanalysis. Dig Dis Sci 2011; 56: 2227-2236 [PMID: 21336601 DOI: 10.1007/s10620-011-1617-y]
81. Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, Wen TF, Xu MQ, Wang WT, Yang JY. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol 2011; 17: 3941-3947 [PMID: 22025883 DOI: 10.3748/wjg.v17.i34.3941]
82. Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, Zhang D, Zhou W. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated metaanalysis. J Hepatol 2010; 53: 508-518 [PMID: 20561699 DOI: 10.1016/j.jhep.2010.03.026]
83. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299: 53-60 [PMID: 18167406 DOI: 10.1001/jama.2007.65]
84. Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res 2010; 29: 18 [PMID: 20196837 DOI: 10.1186/1756-9966-29-18]
85. Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, Ikeda K, Kumada H, Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura Y, Kamatani N, Chayama K. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011; 43: 797-800 [PMID: 21725309 DOI: 10.1038/ng.876]
86. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243]
87. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 2012; 55: 1443-1452 [PMID: 22105560 DOI: 10.1002/hep.24813]
88. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698 [PMID: 22561517 DOI: 10.1038/ng.2256]
89. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760-764 [PMID: 22634756 DOI: 10.1038/ng.2291]
90. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-7392 [PMID: 19723656 DOI: 10.1158/0008-5472. CAN-09-1089]
91. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-1461 [PMID: 18316609 DOI: 10.1158/0008-5472.CAN-07-6013]
92. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51 [PMID: 20175032 DOI: 10.1055/s-0030-1247131]
93. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76 [PMID: 17295177 DOI: 10.1055/s-2006-960171]
94. Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 2012; 39: 473-485 [PMID: 22846864 DOI: 10.1053/j.semin oncol.2012.05.003]
95. Ueyama M, Nishida N, Korenaga M, Korenaga K, Kumagai E, Yanai H, Adachi H, Katsuyama H, Moriyama S, Hamasaki H, Sako A, Sugiyama M, Aoki Y, Imamura M, Murata K, Masaki N, Kawaguchi T, Torimura T, Hyogo H, Aikata H, Ito K, Sumida Y, Kanazawa A, Watada H, Okamoto K, Honda K, Kon K, Kanto T, Mizokami M, Watanabe S. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol 2016; 51: 370-379 [PMID: 26337813 DOI: 10.1007/s00535-015-1116-6]
96. Capone F, Guerriero E, Colonna G, Maio P, Mangia A, Marfella R, Paolisso G, Izzo F, Potenza N, Tomeo L, Castello G, Costantini S. The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. PLoS One 2015; 10: e0134594 [PMID: 26226632 DOI: 10.1371/journal.pone.0134594]
97. Qiao G, Le Y, Li J, Wang L, Shen F. Glycogen synthase kinase-3β is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma. PLoS One 2014; 9: e105624 [PMID: 25157753 DOI: 10.1371/journal.pone.0105624]
98. Stueck AE, Qu Z, Huang MA, Campreciós G, Ferrell LD, Thung SN. Hepatocellular Carcinoma Arising in an HNF-1a-Mutated Adenoma in a 23-Year-Old Woman with Maturity-Onset Diabetes of the Young: A Case Report. Semin Liver Dis 2015; 35: 444-449 [PMID: 26676820 DOI: 10.1055/s-0035-1567827]
99. Ali Kamkar MM, Ahmad R, Alsmadi O, Behbehani K. Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disord 2014; 13: 57 [PMID: 24918094 DOI: 10.1186/2251-6581-13-57]
100. Facciorusso A. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. Curr Diabetes Rev 2013; 9: 382-386 [PMID: 23845075]